SCHEMBL22491682

SCHEMBL22491682

CC(=O)C1CCN(c2ccc(Br)cc2)C1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 2/20 0.49
FPR2 P25090 3/20 0.47
FPR1 P21462 1/20 0.46
RXFP1 Q9HBX9 2/20 0.42
PTPN1 P18031 1/20 0.40
CCR1 P32246 1/20 0.39
CCR2 P41597 1/20 0.39
ALDH1A1 P00352 1/20 0.39
USP30 Q70CQ3 1/20 0.38
ATM Q13315 1/20 0.38
CYP3A4 P08684 3/20 0.37
CYP2C9 P11712 3/20 0.37
CYP2C19 P33261 2/20 0.37
HDAC1 Q13547 2/20 0.37
HDAC8 Q9BY41 2/20 0.37
HDAC6 Q9UBN7 2/20 0.37
KMT2A Q03164 1/20 0.37
LMNA P02545 1/20 0.37
TSHR P16473 1/20 0.37
ALOX15 P16050 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6936690 0.86 PTPN1 (0.52) ROCK2FPR2FPR1RXFP1PTPN1
SCHEMBL5255230 0.85 CCR1 (0.43) ROCK2FPR2FPR1RXFP1CCR1
SCHEMBL14943747 0.84 USP30 (0.51) ROCK2FPR2FPR1PTPN1USP30
SCHEMBL18048749 0.79 ROCK2 (0.56) ROCK2FPR2FPR1RXFP1CCR1
SCHEMBL18048847 0.77 ROCK2 (0.50) ROCK2FPR2FPR1RXFP1ALDH1A1
SCHEMBL25868401 0.77 ROCK2 (0.50) ROCK2FPR2FPR1RXFP1ALDH1A1
SCHEMBL18048717 0.77 ROCK2 (0.50) ROCK2FPR2FPR1RXFP1ALDH1A1
SCHEMBL5846834 0.77 ROCK2 (0.50) ROCK2FPR2FPR1RXFP1ALDH1A1
SCHEMBL20924955 0.76 ROCK2 (0.64) ROCK2FPR2FPR1RXFP1ALDH1A1
SCHEMBL16468325 0.75 ROCK2 (0.48) ROCK2FPR2FPR1RXFP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3717459-B1 COMPOUNDS STEP PHARMA S A S (FR) 2026-01-21 EP disclosed
US-12503466-B2 Aminothiazole compounds as inhibitors of CTPS1 STEP PHARMA S.A.S. (FR) 2025-12-23 US disclosed
US-20240010645-A1 Aminothiazole Compounds as Inhibitors of CTPS1 STEP PHARMA S.A.S. (FR) 2024-01-11 US disclosed
US-11655246-B2 Aminothiazole compounds as inhibitors of CTPS1 STEP PHARMA S.A.S. (FR) 2023-05-23 US disclosed
US-11655246-B2 Aminothiazole compounds as inhibitors of CTPS1 STEP PHARMA S.A.S. (FR) 2023-05-23 US disclosed
US-11655246-B2 Aminothiazole compounds as inhibitors of CTPS1 STEP PHARMA S.A.S. (FR) 2023-05-23 US disclosed
US-20210002269-A1 COMPOUNDS STEP PHARMA S.A.S. (FR) 2021-01-07 US disclosed
US-20210002269-A1 COMPOUNDS STEP PHARMA S.A.S. (FR) 2021-01-07 US disclosed
EP-3717459-A1 COMPOUNDS Step Pharma S.A.S. (FR) 2020-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503466-B2 Aminothiazole compounds as inhibitors of CTPS1 CTPS1, CTPS2, TBXAS1 ROCK2 4478/4885FPR2 4232/4885FPR1 3865/4885
US-11655246-B2 Aminothiazole compounds as inhibitors of CTPS1 CTPS1, CTPS2, TBXAS1 ROCK2 4478/4885FPR2 4232/4885FPR1 3865/4885
US-20210002269-A1 COMPOUNDS UGT1A1, CYP1A1, CYP19A1 ROCK2 4500/4885FPR2 1762/4885FPR1 1056/4885
US-20240010645-A1 Aminothiazole Compounds as Inhibitors of CTPS1 CTPS1, CTPS2, TBXAS1 ROCK2 4478/4885FPR2 4232/4885FPR1 3865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.